Pavella Therapeutics Inc. (PVLA)
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
Palvella Therapeutics, Inc. advances QTORIN rapamycin for microcystic lymphatic malformations, completing NDA submission with strong Phase 3 data and FDA rolling review. Regulatory risk is now significantly reduced, with the FDA awarding a third year of OOPD funding post-positive Phase 3 results and no further efficacy studies required. PVLA's robust $250.6 million cash position supports manufacturing, regulatory, and launch efforts ahead of a targeted US commercial launch in H1 2027.
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel
Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and commercial platform, aiming to expand QTORIN across multiple mTOR-driven dermatological indications, supporting a multi-indication commercial flywheel. Strong liquidity from a recent $230M equity raise enables PVLA to invest in commercialization and pipeline expansion, mitigating typical small biotech funding risks.
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
Palvella Therapeutics Q2 Earnings Call Highlights
Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027.
Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish
Palvella Therapeutics is now a much more credible bet on QTORIN after their positive mLM data. They've also received some FDA feedback, which bodes well for their upcoming NDA submission. PVLA is now targeting a 2H2026 NDA submission for QTORIN rapamycin in mLM.
Palvella Therapeutics Q1 Earnings Call Highlights
Palvella Therapeutics NASDAQ: PVLA said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting what executives described as positive Phase 3 results and outlining an expanded commercial plan supported by a recent $230 million financing.
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
Contrasting Palvella Therapeutics (NASDAQ:PVLA) & Silo Pharma (NASDAQ:SILO)
Silo Pharma (NASDAQ: SILO - Get Free Report) and Palvella Therapeutics (NASDAQ: PVLA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Risk and Volatility Silo Pharma has a
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst
Palvella Therapeutics offers a compelling risk/reward profile, underpinned by strong Phase 2 data and a pivotal Phase 3 catalyst in Q1 2026. Palvella's QTORIN rapamycin platform demonstrates high local efficacy with minimal systemic exposure, validated across multiple rare skin disease indications. With $63.6M in cash and a recent $80M raise, Palvella is well-capitalized to reach key data readouts and NDA preparation, minimizing financing risk.
